Individual Failure Patterns in HS — Why the Same Treatment Fails Differently

The Problem With Uniform Treatment Protocols

Standard HS management follows a broadly consistent protocol regardless of the patient: topical preparations for mild disease, systemic antibiotics for moderate disease, hormonal agents or biologics for severe disease, surgery for established sinus tracts. The protocol is applied based on disease severity rather than disease mechanism. Two patients with Hurley Stage II HS receive essentially the same treatment, even if the internal processes generating their disease are entirely different.

This approach produces a recognisable clinical pattern: some patients respond, many do not, and those who initially respond frequently relapse. But the important observation is not just that these outcomes differ — it is that the way they differ is consistent. Patients with similar internal architectures fail in similar ways. Patients whose HS is primarily driven by gut dysfunction fail differently than patients whose HS is primarily driven by hormonal imbalance. The failure pattern is informative, if it is read correctly.

Pattern One — Initial Response Followed by Rapid Relapse

A significant number of HS patients describe a characteristic experience with antibiotic treatment: the current flare resolves, sometimes rapidly. The skin clears. There is a period — days to weeks — of relative calm. Then the next episode begins. The antibiotic is prescribed again. The cycle repeats.

This pattern — initial response, rapid relapse — is the signature of a condition where the inflammatory driver is internal and continuous, but the treatment is addressing only the current episode's inflammatory expression. The antibiotic reduces the bacterial component of the inflammatory response and the acute inflammatory load. But the internal state that generated the episode — the gut dysbiosis, the immune dysregulation, the elevated androgen baseline — continues unchanged. As soon as the antibiotic's suppressive effect is withdrawn, the same internal environment produces the next episode.

Rapid relapse after antibiotic response is not a sign that the antibiotic was ineffective. It is a sign that the condition being treated is not primarily bacterial — that its driver is internal and systemic, and that antibiotic suppression is addressing a consequence rather than a cause.

What This Pattern Reveals

Patients who fail with this pattern typically have a highly active internal inflammatory driver that is generating new episodes as rapidly as previous ones are suppressed. In practice, this pattern most commonly reflects significant gut dysbiosis producing a continuous inflammatory signal, or a hormonal state — androgen excess, insulin resistance — that is continuously priming the follicular environment for new blockages. The speed of relapse correlates broadly with the intensity of the underlying driver: the faster the relapse, the more active the internal state that needs correction.

Pattern Two — Gradual Escalation Despite Treatment

A second distinct failure pattern is gradual escalation: the patient begins with occasional mild lesions in one location, receives treatment, and the current lesions respond — but over months and years, new locations are involved, episodes become more frequent, and the overall disease burden increases despite ongoing treatment. Each individual episode may be managed, but the disease as a whole is progressing.

This pattern reflects a treatment approach that is managing the output of a progressing disease rather than interrupting the progression itself. The internal drivers — typically a combination of gut dysfunction, hormonal imbalance, and immune dysregulation — are continuing to worsen over time, progressively altering the tissue environment in affected areas and recruiting new areas into the disease process. Treatment is running in parallel with this progression without affecting it.

Patients in this pattern often describe a demoralising experience: they are compliant with their treatment, they attend their appointments, and yet the condition is worse at 35 than it was at 28. This is not a failure of compliance. It is a failure of treatment directionality — the treatment is pointed at the episodes rather than at the trajectory.

Pattern Three — Localised Improvement, Systemic Worsening

A third pattern — less commonly recognised — is localised improvement with systemic worsening. A patient undergoes surgery for established sinus tracts in the underarm area. The surgical site heals well. But within months, new lesions appear in a new location — the groin, the inframammary area, the opposite side. The treated site is improved; the disease as a whole has expanded.

This pattern is almost invariably associated with a treatment approach that has addressed structural consequences without addressing the internal drivers. Surgery removes the existing sinus tract architecture. It does not remove the internal state — the gut inflammatory signal, the hormonal environment, the immune dysregulation — that created the conditions in which those sinus tracts formed. That internal state continues to operate in the remaining susceptible tissue, generating new disease in whatever areas of follicular vulnerability remain.

This is not a criticism of surgery as a tool. It is an observation about what surgery can accomplish on its own. In the absence of concurrent internal correction, surgery resolves the current structural problem while leaving the factory that produced it intact and operating.

Pattern Four — Hormonal Correlation

Some patients exhibit a pattern that is clearly correlated with hormonal cycles: flares that reliably occur before menstruation, worsen during periods of hormonal disruption — pregnancy, perimenopause, changes in contraceptive use — and improve or stabilise during phases of hormonal calm. In these patients, treatments that do not address the hormonal driver consistently fail to produce lasting improvement, even when they produce temporary relief.

The hormonal failure pattern is important because it is often misread as a hormonal condition that requires only hormonal treatment. This is partially correct: the hormonal driver is real and must be addressed. But in most patients with hormonally-driven HS, the hormonal imbalance is itself embedded in a broader metabolic and gut context. Insulin resistance amplifies androgen production. Gut dysbiosis disrupts oestrogen metabolism. Adrenal dysregulation elevates androgen precursors. Treating the hormonal component alone, without addressing its upstream drivers, produces a partial and often temporary correction.

The Layered Nature of Hormonal Failure

Patients who fail hormonal treatments — oral contraceptives, spironolactone, anti-androgens — often find that the treatment produces some initial improvement, then loses effect as the underlying metabolic environment reasserts its influence on hormonal output. The hormonal intervention was real, but it was acting on one level of a multi-level problem. The levels that were not addressed continue to drive hormonal dysregulation independently of the treatment.

Pattern Five — No Initial Response

A smaller but significant group of patients show minimal or no response even to initial treatment. Antibiotics produce no improvement. Hormonal agents produce no improvement. Biologics produce partial or no improvement. These patients are often labelled as refractory and steered toward surgical management or escalated to immunosuppressive regimens.

The absence of initial response is not evidence that the condition is untreatable. It is evidence that the treatments offered are not directed at the actual drivers of the disease in that patient. A patient whose HS is driven primarily by gut dysbiosis and metabolic dysfunction may show no response to hormonal agents — not because they are refractory, but because the hormone-targeted treatment is not addressing the system that is generating their disease. The concept of refractoriness in HS often reflects a mismatch between treatment target and disease driver, rather than true treatment resistance.

What Individual Failure Patterns Tell You

Reading failure patterns correctly is one of the most practically useful skills in managing HS over time. Each pattern points toward the internal architecture of the disease in a specific patient. Rapid relapse after antibiotic response points toward a highly active internal inflammatory driver. Gradual escalation despite treatment points toward uncorrected progression. Localised improvement with new-site involvement points toward untreated systemic drivers following surgical intervention. Hormonal correlation points toward a metabolic-hormonal complex. No initial response points toward a treatment-target mismatch.

These patterns are not diagnostic categories — they are observations that guide evaluation. The specific internal drivers operating in an individual patient require proper assessment. But the failure pattern narrows the field considerably and informs where that assessment should focus.

The Personalisation Imperative

Individual failure patterns are the clearest argument for personalised evaluation in HS. Two patients with superficially identical disease — same stage, same location, same symptom pattern — can have entirely different internal architectures driving their condition. The same treatment applied to both will fail both, but differently, and in ways that reveal what each actually needs.

Personalisation in this context is not a preference or a luxury. It is a clinical necessity dictated by the heterogeneity of the disease's internal drivers. The failure patterns described here are not unusual edge cases — they are the common experience of HS patients who have received protocol-based treatment for years. Recognising them as informative rather than simply frustrating is the beginning of a more productive approach.